Neuromed Pharmaceuticals and Merck & Co., Inc. Announce Agreement for Novel N-type Calcium Channel Compounds
Neuromed Pharmaceuticals Ltd. and Merck & Co., Inc. announced that they have signed a research collaboration and license agreement to research, develop and commercialize novel compounds for the treatment of pain and other neurological disorders, including Neuromed's lead compound, NMED-160, which is currently in Phase II development for the treatment of pain.
Under the terms of the agreement, Neuromed grants Merck an exclusive worldwide license to research, develop and commercialize NMED-160 and other compounds that selectively target the N-type calcium channel. Merck will make a $25 million initial cash payment to Neuromed. Neuromed will also receive research funding from Merck for two years as part of the collaborative research program, including the option to renew for an additional two years. Merck is responsible for all development costs and activities.
The successful development and launch of NMED-160 for an initial single indication on a worldwide basis would trigger milestone payments totaling $202 million. Milestones could increase to approximately $450 million if a further indication for NMED-160 is developed and approved and a further compound is developed and approved for two indications. Neuromed would also receive royalties on worldwide sales of NMED-160 and any additional compounds developed under this agreement. Additional milestone payments would be payable should further compounds be developed. Further financial terms were not disclosed.
Seven of the world's largest pharmaceutical companies have signed up to a groundbreaking consortium aimed at accelerating the development of safe and effective therapies for Parkinson's.
The Critical Path for Parkinson's consortium will bring together leading academics; industry members Abb ... more
Merck, known as MSD outside the United States and Canada, and NewLink Genetics Corporation, confirmed that the third, late-stage, clinical trial of their Ebola vaccine candidate rVSV-ZEBOV-GP (V920) has been initiated in Sierra Leone. The vaccine candidate was originally developed by the Pu ... more
Ablynx announced an extension of its initial two-year research collaboration with Merck & Co., Inc., known as MSD outside the United States and Canada, to develop and commercialise Nanobody® candidates directed towards an undisclosed voltage gated ion channel.Merck & Co., Inc. will extend t ... more
We are inspired by the difference we can make in the lives of people around the world through the innovative medicines, vaccines, and consumer health and animal products we discover and produce. Our products cover a broad range of areas, including heart and respiratory health, infectious di ... more
Neuromed Pharmaceuticals Ltd. announced that it has licensed from ALZA Corporation the exclusive U.S. rights to develop and commercialize OROS(R) Hydromorphone, an extended release formulation of a potent opioid analgesic in Phase 3 clinical development.
Under the terms of the agreement Ne ... more
Neuromed Pharmaceuticals Ltd. and Merck & Co., Inc. announced that they have signed a research collaboration and license agreement to research, develop and commercialize novel compounds for the treatment of pain and other neurological disorders, including Neuromed's lead compound, NMED-160, ... more